ImmunityBio’s stock rose nearly 40% after it announced the Phase I data and Anktiva sales figures for 2025.

Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...

Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles ...

The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...

Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101 ...

Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...

Shares of ImmunityBio IBRX surged 39.8% on Friday and added a further 9.4% in after-hours trading after the company reported updated efficacy and safety data from its ongoing QUILT-106 clinical study ...

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...

Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...